Merck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - MRK

Core Viewpoint - A class action securities lawsuit has been filed against Merck & Co., Inc. due to alleged securities fraud affecting investors between February 3, 2022, and February 3, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Merck investors who were impacted by the company's misleading statements regarding expected revenue of $11 billion from Gardasil sales by 2030 [2] - The complaint highlights that Merck's optimistic forecasts for Gardasil's growth in China were based on the company's confidence in consumer activation and education efforts [2] - On February 4, 2025, Merck announced it would not meet the$11 billion sales target for Gardasil by 2030, citing a halt in shipments to China to reduce inventory due to lower-than-expected demand [2] Group 2: Stock Impact - Following the announcement on February 4, 2025, Merck's stock price dropped from $99.79 per share to$90.74 per share, representing a decline of over 9% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]